Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2025

Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): A multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, Phase 2b trial

Lancet Gastroenterol Hepatol 2025;10:882–95 Doi: 10.1016/S2468-1253(25)00129-3

Peeva E,

Hung KE,

Bojic D,

Lasch K,

Schiffman C,

Feagan BG

Danese et al. report that in the TUSCANY-2 study, afimkibart showed a favourable
benefit–risk profile with clinically meaningful improvements and early onset of response during induction, sustained through maintenance, and an acceptable safety profile with no safety signals. Danese et al. describe results from the Phase 2b TUSCANY-2 trial that evaluated the safety and efficacy of 50mg, 150mg, and 450mg doses of afimkibart in adults with moderately-to-severely active UC.

Keywords:

May 2025

Efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate

Arthritis Rheumatol. 2025 doi: 10.1002/art.43184 Epub ahead of print

Jashi I,

Page K,

Peeva E,

Vincent MS,

Beebe JS

Phase 2 study data show that zimlovisertib + tofacitinib was more effective than tofacitinib alone, in patients with moderate-to-severe RA and an inadequate response to MTX.

Keywords:

September 2023

Efficacité et innocuité du brepocitinib, inhibiteur de TYK2/JAK1, dans le traitement du rhumatisme psoriasique actif : Essai contrôlé randomisé de phase IIb

Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519

Mease P,

Helliwell P,

Silwinska-Stanczyk P,

Miakisz M,

Ostor A,

Peeva E,

Vincent MS,

Sun Q,

Sikirica V,

Winnette R,

Qiu R,

Li G,

Feng G,

Beebe JS,

Martin DA.

Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.

Keywords:

August 2021

Contribution of a European-Prevalent Variant Near CD83 and an East Asian-Prevalent Variant Near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses

Arthritis Rheumatol. 2021;73(7):1155–66

Bing N,

Zhou H,

Chen X,

Kochi Y,

Fujio K,

Zhang B,

Genetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased herpes zoster (HZ) risk.It is well known that HZ risk is elevated in subjects with RA compared with the general population, and that treatment with JAK inhibitors may result in increased risks compared with TNFi and other bDMARD treatments. To this end, Bing, et al. used genome-wide association studies to identify genetic factors associated with an increased risk/faster onset of HZ ...